| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1044500511 |
| P356 | DOI | 10.2165/00003088-199528050-00002 |
| P698 | PubMed publication ID | 7614775 |
| P2093 | author name string | J M Gallo | |
| D Devineni | |||
| P2860 | cites work | The disposition and metabolism of 2',3'-dideoxycytidine, an in vitro inhibitor of human T-lymphotrophic virus type III infectivity, in mice and monkeys | Q45839852 |
| Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2',3'-dideoxycytidine | Q45843343 | ||
| Cellular metabolism of 2',3'-dideoxycytidine, a compound active against human immunodeficiency virus in vitro | Q45848135 | ||
| Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study | Q45875259 | ||
| Initial studies on the cellular pharmacology of 2',3-dideoxycytidine, an inhibitor of HTLV-III infectivity. | Q55243911 | ||
| Pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS and related disorders. | Q64999195 | ||
| Pharmacokinetics of anti-HIV nucleosides in microswine | Q67651876 | ||
| Preliminary pharmacokinetics of 2',3'-dideoxycytidine in neonatal goats | Q69358886 | ||
| Dideoxycytidine permeation and salvage by mouse leukemia cells and human erythrocytes | Q69359689 | ||
| Pharmacokinetics of 2',3'-dideoxycytidine in rats: application to interspecies scale-up | Q69378924 | ||
| Determination of 2',3'-dideoxyadenosine, 2',3'-dideoxyinosine and 2',3'-dideoxycytidine in biological samples | Q69850402 | ||
| Mitochondrial DNA replication does not involve DNA polymerase alpha | Q71524088 | ||
| Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy | Q72216009 | ||
| Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS) | Q22242256 | ||
| 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro | Q24609215 | ||
| An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction | Q28276188 | ||
| In vitro inhibition of the infectivity and replication of human immunodeficiency virus type 1 by combination of antiretroviral 2',3'-dideoxynucleosides and virus-binding inhibitors | Q28323307 | ||
| Pharmacodynamics of 2′,3′-dideoxycytidine: An inhibitor of human immunodeficiency virus | Q28323339 | ||
| Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro | Q28326720 | ||
| Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity | Q28327130 | ||
| Human immunodeficiency virus inhibition is prolonged by 3'-azido-3'-deoxythymidine alternating with 2',3'-dideoxycytidine compared with 3'-azido-3'-deoxythymidine alone | Q28342825 | ||
| Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides | Q28360374 | ||
| Ribavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro | Q28361577 | ||
| Frequent Detection and Isolation of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and at Risk for AIDS | Q29614260 | ||
| The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial | Q29620785 | ||
| The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial | Q29620805 | ||
| Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). | Q33444047 | ||
| Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency | Q34055177 | ||
| Nucleosides. IX. The Formation of 2',3'-Unsaturated Pyrimidine Nucleosides via a Novel β-Elimination Reaction1,2 | Q34241399 | ||
| Isolation of Lymphocytopathic Retroviruses from San Francisco Patients with AIDS | Q34250436 | ||
| Disseminated Kaposi's sarcoma in homosexual men. | Q34253447 | ||
| Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides | Q34506987 | ||
| Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2',3'-dideoxynucleosides in vitro | Q34610200 | ||
| Zidovudine intolerance. | Q37947318 | ||
| Strategies for antiviral therapy in AIDS. | Q38172146 | ||
| A human T-lymphotropic retrovirus (HTLV-III) as the cause of the acquired immunodeficiency syndrome | Q39016053 | ||
| Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders. A progress report | Q39755409 | ||
| Zalcitabine | Q40709556 | ||
| Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study | Q40778496 | ||
| Severe Acquired Immunodeficiency in Male Homosexuals, Manifested by Chronic Perianal Ulcerative Herpes Simplex Lesions | Q40849251 | ||
| The in vitro and in vivo anti-retrovirus activity, and intracellular metabolism of 3'-azido-2',3'-dideoxythymidine and 2',3'-dideoxycytidine are highly dependent on the cell species | Q42200271 | ||
| Synergistic interaction of 2',3'-dideoxycytidine and recombinant interferon-alpha-A on replication of human immunodeficiency virus type 1. | Q42200603 | ||
| Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex. | Q42284384 | ||
| Genetic analysis of 2',3'-dideoxycytidine incorporation into cultured human T lymphoblasts | Q42817658 | ||
| Dideoxycytidine alone and in an alternating schedule with zidovudine in children with symptomatic human immunodeficiency virus infection | Q43514070 | ||
| Restricted transport of 3'-azido-3'-deoxythymidine and dideoxynucleosides through the blood-brain barrier | Q43805805 | ||
| In vitro toxicity and metabolism of 2',3'-dideoxycytidine, an inhibitor of human immunodeficiency virus infectivity | Q44079869 | ||
| A pilot study of the bioavailability and pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS or AIDS-related complex | Q44250538 | ||
| Pharmacokinetic evaluation of drug interactions with anti-human immunodeficiency virus drugs. V. Effect of soluble CD4 on 2',3'-dideoxycytidine kinetics in monkeys | Q44696573 | ||
| P433 | issue | 5 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 351-360 | |
| P577 | publication date | 1995-05-01 | |
| P1433 | published in | Clinical Pharmacokinetics | Q5133788 |
| P1476 | title | Zalcitabine. Clinical pharmacokinetics and efficacy. | |
| P478 | volume | 28 |
| Q30887008 | A novel action of human apurinic/apyrimidinic endonuclease: excision of L-configuration deoxyribonucleoside analogs from the 3' termini of DNA. |
| Q33933498 | Development and optimization of anti-HIV nucleoside analogs and prodrugs: A review of their cellular pharmacology, structure-activity relationships and pharmacokinetics |
| Q41066477 | Drug interactions with antiviral drugs |
| Q36239813 | Mitochondrial dysfunction and antiretroviral nucleoside analog toxicities: what is the evidence? |
| Q33933495 | P-glycoprotein, secretory transport, and other barriers to the oral delivery of anti-HIV drugs |
| Q39558483 | Pharmacokinetics and distribution over the blood-brain barrier of zalcitabine (2',3'-dideoxycytidine) and BEA005 (2', 3'-dideoxy-3'-hydroxymethylcytidine) in rats, studied by microdialysis |
| Q84534725 | Renal excretion of apricitabine in rats: ex vivo and in vivo studies |
| Q43744211 | Testing the reverse transcriptase model of somatic mutation |
| Q36130623 | Use of highly active antiretroviral therapy in patients with renal insufficiency |
| Q36851934 | Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions |
| Q41494492 | Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection |
Search more.